Background: A few data are available from analyses of the complications and costs of central venous access ports for chemotherapy. This prospective study deals with the complications and global costs of central venous ports connected to a Groshong catheter for deliverance of long-term chemotherapy.
Introduction
Many cancer patients require long-term central venous access for the safe delivery of chemotherapeutic agents, transfusion of blood and blood products, and the performiance of laboratory tests. The choice of the device is usually made by the treating physician on the basis of retrospective reviews of the morbidity and longevity of various devices, hospital or surgical availability, as well as personal experience. Together with percutaneous tunneled catheters, such as those of Hickman and Broviac, there has been increased demand for totally implantable access ports (TIAP) because they need no external dressing, allow patient activity and require only monthly flushes of heparinized saline to keep the catheter patent. An obvious disadvantage of these devices is the fact that they are much more expensive than tunneled catheters; moreover, the crude cost of the commercially available devices does not take into account the additional costs of catheter maintenance and the treatment of possible complications. There are only a few studies and only little data concerning the total cost of these systems, especially when prospectively assessed [1] ; in addition, most studies do not exhibit sufficient follow-up, whereas it is well known that a number of late port-related complications arise some months after implantation. Only a little economic information about these devices and their related morbidity could lead to an underestimation of their global cost. The purpose of this study is to provide clinicians with data on the total cost of TIAP for long-term chemotherapy, derived from a prospective study of 333 devices with a minimum of 180 days of follow-up. Follow-up continued until the device was removed, the patient died or the study was closed (30 September 1997); patients with uneventful implant and subsequent follow-up of less than 180 days were not considered for this study.
Patients and methods

Three hundred thirty-three ports placed in patients at the European Institute of Oncology in
Two-hundred ninety-six devices were implanted in the operating room under fluoroscopic control, even if the patient was treated and monitored in a day-hospital setting, and 37 in an angiographic suite. Preoperative evaluation included a history and physical examination that focused on possible anatomic pitfalls (clavicle fracture, cervical or mediastinal adenopathy, chest wall tumours, presence of rotation flaps as part of head and neck reconstructive surgery), body habitus and vascular access history (side used and pneumothorax history, previous line infection). The only laboratory studies requested as absolutely necessary were a complete blood count, including platelet count and differential, and coagulation tests. All of the patients had chest radiographs for preoperative identification of mass lesions or anatomic anomalies. The patients received a local anesthesia, without routine additional intravenous sedation; a single dose (2 g) of Cefazoline sodium was given intravenous 15 minutes before implant. No breaks in operative technique or instrument sterility were documented; a confirmatory chest X-ray was always obtained after the placement and all patients were checked by a physician before discharge.
To minimize possible variables related to the devices adopted, a single type of port was used, constructed of titanium and silicone rubber (Dome Port®, Bard Inc., Salt Lake City, USA) with 8 F silastic Groshong® catheter tubing (Bard Inc., Salt Lake City, USA). Developed in 1978, the Groshong catheter is a silicone rubber device with a three-position pressure-sensitive valve near the distal tip. The valve opens only with positive or negative pressure, effectively preventing spontaneous reflux of blood or inadvertent air embolism. This unique feature renders this catheter the most expensive of the commercially available ones.
A central venous access form was filled in by the operator after the procedure. Data from the follow-up of these patients were entered into the form and collected in a software registry. The time interval between implant of catheter and first chemotherapy delivered through the device was usually 24 hours; if an early complication was found (e.g., pneumothorax), the start of chemotherapy was delayed until resolution of the problem (generally 48-72 hours after implantation).
Complications were divided into two main categories: (1) early (intraoperative and postimplantation period to first use), and (2) late complications (occurring after the first chemotherapy course given through the device).
Blood screening for bacteremia has not been performed at regular intervals, since blood sampling for microbiology was obtained when clinically suggested (unexplained fever and/or signs of sepsis). Criteria for the diagnosis of device-related bacteremia were defined as: a) greater than a 10-fold increase in colony-forming units (CFU) of bacteria per ml of blood obtained through the device in comparison to peripheral blood cultures; b) greater than 1,000 CFUs of bacteria obtained through the device, in the absence of peripheral blood cultures; or c) positive catheter tip culture upon removal in the appropriate clinical setting. Device-related bacteremia or fungemia was considered cured when culture results were negative at the termination of antibiotic therapy and no evidence of clinical infection had been seen by two weeks later.
Port pocket infection was defined as induration, erythema, and tenderness around the port with culture-positive material aspirated from the port pocket.
Cutaneous site infection was defined as induration, erythema, or tenderness and exudate at the port surface needle access site.
Thrombosis was identified with ultrasound and/or venography when clinically suggested by progressive arm or facial swelling.
The average purchase cost of the devices was obtained from the hospital charges, based on the prices applied by the manufacturer during the 30-month period of the study. Insertion and maintenance costs were estimated by obtaining the charges for an average TIAP implant and its subsequent use. Although not strictly recommended by the manufacturer, implanted ports have been filled with sterile heparinized saline after each use to prevent clot formation and catheter blockage. The following schedule was adopted: after each infusion of medication or blood withdrawal: 20 ml sterile normal saline, then 5 ml heparinized saline (50 IU/ml); for ports not in use: 5 ml of heparinized saline (50 IU/ml), once every 28 days. This maintenance programme has been carried out on an outpatient basis by a experienced nursing staff. The costs of complication management were assessed analytically, providing the overall amount of related costs when more than one case of a complication was observed. The total cost for each device was defined as the purchase cost plus the insertion cost plus the maintenance cost plus the cost of complication treatments, if any. The costs of removing the TIAP and new implanting were also included in the economic analysis when required by the treatment of the complication. Other charges incurred by the patients in this study were not included in the cost analysis, because it was not possible to accurately attribute them to the TIAP or to other ongoing problems (e.g., febrile neutropenia).
Results
Three hundred thirty-three devices, comprising a total of 79,178 days in situ, were placed in 328 patients (five patients underwent a second placement after removal of the first device). All patients received at least one cycle of chemotherapy through the TIAP. Adequate follow-up was obtained in all cases (median 237 days, range 180-732). Table 1 summarizes pertinent population data and route for central venous access; we observed no TIAP- related deaths in this series. Six of 10 patients in whom a pneumothorax was seen as a complication of the TIAP placement underwent a tube-thoracostomy, with no additional morbidity (our policy was to insert a chest-tube when the pneumothorax was large (more than 30%) and /or symptoms were relevant).
Four patients of this series had an accidental arterial puncture during the implant procedure, which, however, caused no significant complications or additional cost.
In four cases we had to revise the implant, without removal, because of malfunction of the catheter due to a narrowing of the lumen (two cases), dislocation into the controlateral brachio-cephalic vein (one case) and ipsilateral giugular vein (one case). An early catheter obstruction was detected in two cases.
Catheter rupture and embolization occurred in five cases (1.5%, 0.063/1000 days of port use); two patients had palpitations and chest discomfort 66 ± 18 days after implant, during a pause between subsequent chemotherapy cycles, leading to chest X-ray and diagnosis. Three patients were completely asymptomatic and incidental chest radiographic examination performed for re-staging detected the catheter embolization. Retrieval of embolizing catheters was accomplished without additional morbidity by venous transfemoral approach using a modified Dormia device to seize the catheter piece and pull it out.
The incidence of catheter-associated venous thrombosis was 1.5% in this series (five patients, 0.063/1000 days of port use); all of the patients exhibited ipsilateral arm swelling, without neurologic difficulties in the extremity. The interval between implantation and the onset of clinically evident venous thrombosis was less than 30 days in all patients. Duplex ultrasonography yielded a positive result, confirmed by a standard contrast venogram of the ipsilateral extremity. As the catheters were still needed, patients were treated with intravenous continuous infusion of heparin for three days or low molecular weight heparin subcutaneous for five days, then oral anticoagulation was begun and full anticoagulation was continued for three months. The first patient died 11 months after port placement for progression of her neoplastic disease, whereas the rest are still alive with a progressive disease nine to 20 months after implant. tive cocci, suggests direct inoculation or migration of organisms along the accessing needle as the primary mechanism; such infection occurred in one case (0.3%, 0.012/1000 days of port use) and was successfully treated by administration of appropriate antibiotics, first with empiric coverage and then targeted for the cultured organism (coagulase-negative Staphylococcus aures).
Eight patients suffered port-related bacteremia (2.4%, 0.101/1000 days of port use), leading to port removal in six cases (1.8%); causative agents were Bacillus subtilis (one case, port removed), coagulase-negative Staphylococcus aures (five cases, four ports removed, one retained after elimination of the clinical sepsis syndrome by antibiotic therapy), Streptococcus lactaceae (one case, retained after elimination of the clinical sepsis syndrome by antibiotic therapy) and an unknown agent (port removed for clinical sepsis in another hospital). The median number of days (SD) before start of the infection was 165 [20] . Table 2 shows the costs as determined by this study of implanting a TIAP; our initial experience in the use of TIAP connected to Groshong catheter in cancer patients undergoing chemotherapy has been presented elsewhere in a paper dealing with a prospectively-studied consecutive series of 178 unselected oncology patients treated in a single Institution [2] .
The costs of diagnosis and management of early complications are listed in Table 3 ; as expected, the costs have proven to be much higher when a tube thoracostomy was required for the proper treatment of a pneumothorax (six patients out of 10; US$1827 vs. 535). Early revision of the devices, mostly caused by kinking/ obstruction or dislocation of the catheters, accounted for a total of six patients, and required a new operatingroom procedure. The total cost for its management was USS3825. The global cost for diagnosing and treating early complications was USS 16,927.
Catheter rupture and embolization were observed in five of the patients in this series; the costs for their management (interventional radiology), totaling USS5913, are listed in Table 4a. Table 4b lists the analytically-assessed costs for treatment of venous thrombosis, which took place in five patients of the series and amounted to US$9199. Pocket infection was observed in one case in which treatment was on an outpatient basis, which limited the cost to US$85 (Table 4c ). The costs for treatment of skin erosion without infection, which was also detected in one case and required a new implant procedure in the operating theatre were considerably higher (US$872, Table 4d) . Tables 4e and f shows the costs of treatment of portrelated bacteremia; it cost more than US$2000 to treat one patient suffering from this complication, either when the port was removed after a proper course of antibiotics or when antibiotics alone were administered.
Finally, Table 5 summarizes the total cost of US$1970 per patient, treated for a six-month period, including the cost of purchase and implantation, the cost of treatment of early and late complications and device maintenance cost.
Discussion
The use of central venous access devices has become an essential component of the treatment of many medical disorders. It is estimated that several million devices are inserted each year, facilitating many emerging therapies, including long-term chemotherapy. TIAP are the last type of long-term venous access developed, after the proposal of tunneled, cuffed silastic catheters by Broviac Table 5 . Global cost of purchase, implant and maintenance of T1AP in this series.
1.
2.
3.
Cost of single port purchase and implanting (Table 2 When compared to those of tunneled catheters, port infections tend to be uncommon, although results are sometimes conflicting [3] and most series reflect differences in the type of adopted device and the patients being treated rather than any inherent superiority of one device over another. Another important point is the cost of purchase and use of these devices; a case-control study comparing durability and cost between TIAP and percutaneous silicone catheters showed a significantly greater total cost of TIAP (US$2233 vs. 1453) [4] ; however, as the TIAP were found to function for a significantly longer time, they proved less expensive on a per diem basis, with a break point that occurs at approximately six months, the minimum follow-up of the present study. The major cost of TIAP compared to tunnneled-external devices should be balanced against the theoretical advantage of the former in terms of reduced complication rate and greater durability. An analytical assessment of the costs of purchase, implant and maintenance of TIAP has been carried out in the present study, with reference to the present situation of actual costs in the European Institute of Oncology in Milano. As a consequence, these costs might not completely reflect national, provincial or other price agreements or reimbursements, and may not be comparable with those applied in other countries or institutions. Moreover, the costs deriving from the proper treatment of every complication related to implant and use of such devices have been included. Importantly, the purchase cost of the device we have adopted in this series has proven to be the highest among the commercially available ones because of the distinguishing characteristics of the catheter.
The early complications of subclavian venipunclure include pneumothorax, hemothorax, air embolism and arterial perforation causing a clinically relevant bleeding. Only pneumothorax has been observed in the present series (10 cases, 3.3%; with six of 10 = 1.8% of tube-thoracostomies), while we had no cases of significant hemorrhage related to TIAP placement. According to the literature, pneumothorax occurs in 1% to 4% of subclavian line insertions; careful attention to anatomic landmarks and operator experience during the placement of central venous catheters are most important for avoidance of this complication during subclavian vein catheterization. From published reports and in our experience as many as 50% of asymptomatic, small pneumothoraxes (less than 30% of the pleural space) can be treated conservatively, without tube thoracostomy, with a significant reduction of the costs (USS535 vs. $1827, Table 3a and b). Surgical cutdown of the cephalic vein in the deltoid-pectoralis space was adopted as an effective alternative option to the percutaneous approach to subclavian vein in 36 cases (10.8%), particularly in patients with difficult anatomical landmarks (for instance, obesity or previous surgery in the region). This approach averts the risk of pneumothorax, but significantly increases the median time required to complete the procedure as well as the stress for the conscious patient. Since the percutaneous placement can be performed much more quickly and with safety, comparable to that of an open venous cutdown, our policy was to confine the open approach to difficult cases, after uneventful attempts at percutaneous incannulation. Occasionally, in patients with refractory thrombocytopenia who do not respond well to platelet transfusion but need long-term venous access, venous cutdown on the cephalic as well as external jugular vein may be the safest approach. Although 'blind' insertion of the catheter could avert the additional cost of ultrasound or fluoroscopy, the routine use of fluoroscopy in this series allowed us to limit to six cases (1.8%) the time-consuming, patientstressing and very expensive replacements after implant, due to an incorrect catheter position (most often ipsilateral internal jugular or controlateral brachiocephalic vein) or to the kinking of a tube.
Infection is the most common complication of venous access catheters and the leading reason for their removal. Catheter-related infections are reported in 11% to 45% of patients with Hickman catheters [5, 6] , 0% to 22% of patients with TIAP [7] and 7% to 32% of patients with Groshong catheters [5, 7, [8] [9] [10] [11] [12] . Device-related morbidity from the literature is difficult to compare because of varying definitions and dissimilar patient populations. While several retrospective studies have noted higher infection rates for external devices compared to TIAP in select patient populations [13] , a prospective randomized study was unable to demonstrate a statistically significant difference in infections [6] . They appeared much higher for both Hickman catheters and ports than in many other reports, probably due in part to a study population that included many patients with hematologic malignancies. The time period of follow-up in the study may also introduce bias, because other studies have shown a progressive difference in infection rates between the two types of venous access devices after six months, which should therefore be considered the gold-standard period of follow-up for evaluating the long-term effectiveness of these devices. However, in a randomized study of infectious morbidity in patients with solid tumors, TIAP were shown to be associated with fewer infections than were catheters [14] , Data from our work, derived from a prospective not randomized study, support the conclusions of most retrospective papers: the infectious morbidity related to TIAP is reasonably low, even in patients undergoing cytostatic treatments for solid tumors. The mechanisms of devicerelated infection may explain why TIAP are less likely to be associated with infection than are tunneled catheters. Migration of skin flora through the cutaneous insertion site with catheter colonization is supported by the finding that gram-positive organisms, especially coagulasenegative staphylococci, are responsible for a significant percentage of the cases of device-related bacteremia in patients with catheters. Compared with catheters, TIAP are irrigated less frequently, require no home care, and are less prone to environmental or cutaneous contamination when not accessed. All these factors may contribute to the reduced incidence of infections associated with TIAP.
The incidence of catheter-related symptomatic venous thrombosis has proven very low in this study (1.5%, Table 4b ); no useful data are available from retrospective analyses of clinical and autopsy reports in the medical literature, where the incidence varied from 0% to 50% [15, 16] . In a controlled randomized trial, prospective venography.was performed as part of a study of prophylactic low-dose warfarin treatment, with a symptomatic thrombosis rate in untreated patients of 12.5% and an overall rate (symptomatic + silent) of 38% (15 of 40) [17] . Another prospective study in cancer patients with Port-a-Cath® subclavian venous catheters reported a 62% rate of upper extremity deep vein thrombosis in the control group, and 6% in patients taking 2500 IU subcutaneous of Fragmin® once daily for 90 days (relative risk 6.75, P = 0.002, Fisher exact test [18] ). Clinical data derived from our study are not fully comparable, due to differences in adopted devices; however, they do not support the routine use of lowdose anticoagulants in patients bearing a TIAP, the cost of which would be significantly higher than that of the proper treatment of 1.5% venous thromboses complicating the post-implant course (extended up to six months); this cost is estimated at US$40 per patient throughout six months (US$13,120 to prophylactically treat 328 patients for a minimum of six months), without taking into account the possible costs related to diagnosis and treatment of the side effects of anticoagulants.
Venous access devices placed through a subclavian vein catheterisation may be compressed by neighboring bony structures, leading to biomaterial fatigue, catheter fracture at the compression point and embolization of the fragment into the central venous system. This complication occurred in five of the patients in our series; it has also been called 'catheter pinch-off and the radiologic finding of acute compression of the catheter is quite typical, indicating a catheter at high risk that should be removed as soon as possible [19] . Clinically it may be associated with intermittent catheter dysfunction, and can be improved by changes in the patient's shoulder position; this situation is not specific and can also be commonly seen when a fibrin sheath has formed around the catheter tip [20] . The most important factor in avoiding this complication is technique, such that the subclavian vein is always accessed lateral to the bend in the clavicle, far away from the ligament joining the clavicle and the first rib. However, catheter fracture and embolization is also possible when the pinch-off sign is not seen, and precisely that was observed in at least four patients of our series. The complication may be completely asymptomatic, and there are no reported fatalities from it in the medical literature. Table 4a shows the relatively low cost of treating this complication: of course, the cost of a new implant has to be added, should this choice be adopted.
In summary, we have shown that US$2000 is sufficient to give a patient six months of chemotherapy using the most expensive commercially available TIAP, except for the crude costs of the drugs. Single institution data might differ from those gathered at other centres and might not apply to most practitioners; however, the results of this study are particularly relevant because they have been obtained through an accurate cost analysis of the largest published clinical series of TIAP connected to a Groshong catheter. According to the present study, TIAP connected to a Groshong catheter are associated with high purchase and insertion charges, a low rate of complications and low maintenance costs. Although optimal management of complications, optimal device and optimal timing of implant have not been addressed by the present paper (these need to be defined by multicentric randomised trials), the results of this study support the increasing use of TIAP in current oncology medical practice.
